Vivek Subbiah: Optimizing Tomorrow’s Drug Development with Project Optimus
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA), shared a post on LinkedIn:
“Optimising Tomorrow’s Drug Development with Project Optimus: Precision Dosing IS Precision Oncology – Editorial in Annals of Oncology.
- Project Optimus, spearheaded by the US FDA’s Oncology Center of Excellence, represents a paradigm shift in the approach to oncologic drug development.
- With a primary focus on optimizing dosage to maximize therapeutic benefits while minimizing toxicity, Project Optimus introduces key recommendations for sponsors and drug developers.”
Optimizing Tomorrow’s Drug Development with Project Optimus: Precision Dosing IS Precision Oncology
Author: Vivek Subbiah
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer. He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials. He has also received the Yvonne Award 2024 by OncoDaily in the “Voice of Oncology” category.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023